Skip to Main Content

Flagship Pioneering, the Cambridge, Mass., venture capital firm, brought biotech startup Laronde out of stealth mode in May, launching it with $50 million after four years of secrecy.

It was the first time Laronde disclosed its technology: a proprietary molecule its scientists call “endless RNA,” which the company hopes will allow humans to produce their own proteins for weeks or months to treat diseases. Now, three months after making its public debut, Laronde announced it has raised $440 million from investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment